AR033862A1 - MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT - Google Patents

MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT

Info

Publication number
AR033862A1
AR033862A1 ARP020100515A ARP020100515A AR033862A1 AR 033862 A1 AR033862 A1 AR 033862A1 AR P020100515 A ARP020100515 A AR P020100515A AR P020100515 A ARP020100515 A AR P020100515A AR 033862 A1 AR033862 A1 AR 033862A1
Authority
AR
Argentina
Prior art keywords
formulation containing
muscarinic agonist
medicinal formulation
agonist agent
talsaclidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ARP020100515A
Other languages
Spanish (es)
Inventor
Karoline Dr Bechtold-Peters
Thomas Friedl
Michael Dr Walz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR033862A1 publication Critical patent/AR033862A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

Formulación de medicamento que contiene talsaclidina 1', que consta de un núcleo que contiene la sustancia activa talsaclidina y un revestimiento de película que envuelve a éste núcleo.Medication formulation containing 1 'talsaclidine, which consists of a nucleus containing the active substance talsaclidine and a film coating that envelops this nucleus.

ARP020100515A 2001-02-15 2002-02-15 MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT Withdrawn AR033862A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10106971A DE10106971A1 (en) 2001-02-15 2001-02-15 Drug formulation containing a muscarinic agonist

Publications (1)

Publication Number Publication Date
AR033862A1 true AR033862A1 (en) 2004-01-07

Family

ID=7674095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100515A Withdrawn AR033862A1 (en) 2001-02-15 2002-02-15 MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT

Country Status (9)

Country Link
EP (1) EP1361871A2 (en)
JP (1) JP2004518710A (en)
AR (1) AR033862A1 (en)
AU (1) AU2002247705A1 (en)
CA (1) CA2434976A1 (en)
DE (1) DE10106971A1 (en)
MX (1) MXPA03007272A (en)
UY (1) UY27170A1 (en)
WO (1) WO2002064124A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2140867T2 (en) 2007-03-29 2023-10-30 Daiichi Sankyo Company, Limited Pharmaceutical composition
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
KR101792299B1 (en) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 Method for improving dissolution of anticoagulant agent
CN103732227B (en) 2011-08-10 2017-04-12 第一三共株式会社 Pharmaceutical composition containing diamine derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3839385A1 (en) * 1988-11-22 1990-05-23 Boehringer Ingelheim Kg NEW QUINUCLIDINES, THEIR MANUFACTURE AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
WO1998046225A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Method for treating schizophrenia
WO1998046601A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
DE19851126A1 (en) * 1998-11-06 2000-05-11 Boehringer Ingelheim Pharma Use of talsaclidine for treating schizophrenia

Also Published As

Publication number Publication date
AU2002247705A1 (en) 2002-08-28
WO2002064124A3 (en) 2002-12-05
WO2002064124A2 (en) 2002-08-22
UY27170A1 (en) 2002-09-30
MXPA03007272A (en) 2003-12-04
EP1361871A2 (en) 2003-11-19
JP2004518710A (en) 2004-06-24
DE10106971A1 (en) 2002-08-29
CA2434976A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
ATE293995T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THAT PROMOTE DRUG ABSORPTION
PT1183014E (en) ORAL PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED LIBERATION AND TISSUE DISSIMULATION
HUP0002797A2 (en) Sustained release drug delivery devices
TNSN95076A1 (en) DOSAGE FORM II OF MULTIPLE TABLET UNIT
DK1102579T3 (en) Medical aerosol formulations
DE60335557D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINED AN OPIOIDANAL GETIC
CY1116429T1 (en) LEATHER FOR LEATHER AND INTERMEDIATE ADMINISTRATION OF ACTIVE INGREDIENTS
DZ2964A1 (en) New substituted diphenylureas, and pharmaceutical compositions containing them.
MX9600857A (en) Multiple unit tableted dosage form i.
DE69942154D1 (en) MEDICATION-COMPATIBLE COMPOSITION IN AEROSOL FORM
DE69811278D1 (en) Gastric juice-protected omeprazole microgranules, manufacturing process and pharmaceutical preparations
BRPI0408655A (en) formulations comprising an active agent and cocoa powder and their use
DE60142305D1 (en) PHARMACEUTICAL PREPARATION CONTAINING N-Ä2- (1,6,7,8-TETRAHYDRO-2H-INDENOE4,4 BÜFURAN-8-YL) ETHYL PROPIONAMIDE COATED WITH A COPOLYVIDONE-CONTAINING, POLYETHYLENE GLYCLE-FREE PACKAGING
BR0207654A (en) Composition comprising a base cream or lotion
AR033862A1 (en) MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT
DE60002089D1 (en) LOW-DOSED TABLETS AND METHOD FOR THE PRODUCTION THEREOF
ATE158172T1 (en) POWDER PHARMACEUTICAL COMPOSITION
ES2113985T3 (en) COATING MATERIAL FOR DRUG FORMS OF ORAL ADMINISTRATION.
FR2826367B1 (en) NOVEL 4- (4-CYANOBENZOYL) PHENYL] GLYCOPYRANOSIDE DERIVATIVES, USE AS MEDICAMENT, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
RS52027B (en) Enterosolvent tablets with acetylsalicylic acid
JO1880B1 (en) Multiple Unit Tableted Dosage Form I

Legal Events

Date Code Title Description
FA Abandonment or withdrawal